XW04378
Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
Introduce Tabelecleucel in Central Vein, Perc, New Tech 8
Axis Breakdown
Every ICD-10-PCS code is exactly seven characters, one per axis. Each character's meaning is defined by its position in the code.
| Position | Value | Meaning |
|---|---|---|
| 1 | SectionX | New Technology |
| 2 | Body SystemW | Anatomical Regions |
| 3 | Root Operation0 | Introduction Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products |
| 4 | Body Part4 | Central Vein |
| 5 | Approach3 | Percutaneous |
| 6 | Device / Substance / Technology7 | Tabelecleucel Immunotherapy |
| 7 | New Technology Group8 | New Technology Group 8 |
Potential MS-DRG Relationships (FY2026)
The MS-DRG grouper treats this as a non-operating-room procedure. It appears in the surgical logic of 1 MS-DRG:
- MDC PRE — Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies: DRG 018
From the CMS MS-DRG Definitions Manual, Appendix E. Actual DRG assignment depends on the complete claim.
Contextual Map
Every relationship of XW04378 in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.
PCS table
- XW0[PCS table]
- [object Object] — Section: [object Object] [Section]: “[object Object]”
- [object Object] — Body System: [object Object] [Body System]: “[object Object]”
- [object Object] — Operation: [object Object] [Operation]: “[object Object]”
MS-DRG participation
- DRG 018 — CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL AND OTHER IMMUNOTHERAPIES [MS-DRG]: “CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL AND OTHER IMMUNOTHERAPIES — Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies (MDC PRE)”
MDC crossing · diagnoses (1333)
- Pre-MDC[MDC crossing]: “Pre-MDC — the grouper's crossing between diagnoses and procedures: a principal diagnosis sets the MDC, and same-MDC procedures move the stay to its surgical DRGs.”
- A36.0 — Pharyngeal diphtheria [Same-MDC diagnosis]: “Pharyngeal diphtheria — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
- A36.1 — Nasopharyngeal diphtheria [Same-MDC diagnosis]: “Nasopharyngeal diphtheria — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
- A36.2 — Laryngeal diphtheria [Same-MDC diagnosis]: “Laryngeal diphtheria — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
- A54.5 — Gonococcal pharyngitis [Same-MDC diagnosis]: “Gonococcal pharyngitis — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
- A56.4 — Chlamydial infection of pharynx [Same-MDC diagnosis]: “Chlamydial infection of pharynx — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
- and 1328 more
Nearest codes
- XW03378 — Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8 [One axis away]
- XW04308 — Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8 [One axis away]
- XW04358 — Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8 [One axis away]
- XW04368 — Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8 [One axis away]
- XW04372 — Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2 [One axis away]
- XW04377 — Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7 [One axis away]
- XW04388 — Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8 [One axis away]
- XW04398 — Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8 [One axis away]
Change history
No changes recorded for this code — unchanged since the FY2026 (April) baseline of the change ledger.